Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
about
Design of Phase II cancer trials evaluating survival probabilitiesPotent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine KinaseEnzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinomaAntineoplastic agents and thrombotic microangiopathy.Review article: current treatment and optimal patient management in pancreatic cancer.A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models.Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case reportA combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.Gemcitabine and platinum combinations in pancreatic cancer.Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 StudyA randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.Gemcitabine-induced thrombotic microangiopathy.Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.Gemcitabine-associated thrombotic microangiopathy in a patient with lung cancer: A case reportAnalytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Chemotherapy for upper gastrointestinal tumours.Novel non-operative treatment and treatment strategies in pancreatic cancer.Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreasPancreatic cancer: the evolving role of systemic therapy.Phase II study of gemcitabine in patients with advanced pancreatic cancer.Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.The pemetrexed/gemcitabine combination in pancreatic cancer.Systemic therapy for metastatic pancreatic adenocarcinoma.The way forward in treating pancreatic cancerDevelopments in the systemic therapy of pancreatic cancer.Recent developments in the pharmacological treatment of advanced pancreatic cancer.Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy.Emerging drugs in pancreatic cancer.Hepatic arterial therapy with drug-eluting beads in the management of metastatic pancreatic carcinoma to the liver: a multi-institutional registry.
P2860
Q24802587-A8142FB6-DAD9-4EE7-8D42-1A80DA1ED43DQ28550404-CB48D478-31C7-4E5C-AAB4-51A5D29ED74DQ29616287-8317D8F4-FB46-48B0-88DD-B84E2FAAC5B9Q30251919-596054D7-3641-4E7B-ACD6-58EA9FBEFDE3Q30431857-845FD484-1073-4207-80FF-FB24DC96764FQ30438645-F49CF1B9-843F-411C-B14D-BF6173D2B7DBQ31927266-3B9DF2F3-86CF-42C2-A4EE-940A7E8565ECQ33265964-429FABD2-C995-44E1-B89C-A72D2C970848Q33310804-0BACBA42-3667-4E42-9284-3362F5EF105BQ33328421-4DDC7E76-142D-428F-8EFF-51A1667E15A2Q33329493-7F520F1A-823D-43D6-9400-32A445C23EDFQ33338244-6915EF0B-66DC-4501-8014-F12EDA1F9063Q33338535-97F4303C-0316-47B2-B605-DBBB0B43DB20Q33340185-F25811D6-2E3D-43FB-887B-FE7282FFCE6CQ33344048-1312FE5B-97ED-479C-8D9D-56F9B5973186Q33357102-960A486D-39CB-4D02-899C-D3AB76B55FA8Q33385766-719E697D-6619-4E65-B49F-E6B8B54052D7Q33401816-C50D175B-5B48-430E-A379-AD46D78E37F5Q33409519-78EDFFE8-6CE7-4D3F-822B-6B2B73222B6DQ33411493-9E898BBC-DC81-4710-9CF6-3BB5DEDDDA08Q33413284-C2C58599-05AB-4666-95C7-0CA49210EF3DQ33434397-7BEADED6-01C3-4046-93F1-FE954B456EC5Q33441480-C1146EC2-2FCF-4CEC-B3D7-2C2307364CFAQ33520977-D6FB0B5C-41A4-4645-8A14-529756010CC1Q33632330-24E2BA48-E8FB-4161-A873-57D6937584ACQ33925836-E939C332-5CCC-4917-9FA4-F3D194AB9C26Q34074879-0DF62452-D15D-4754-B9A1-1AC1B3C0DECDQ34449812-ABCB0F08-F98A-4756-9A89-FCE1428345E4Q34515547-D15A2E54-597F-4F15-82BC-7A4C6603FBA5Q34732138-417E82F8-A9C6-43F2-85C3-A08EB8631B0BQ34810745-894479D6-23AE-4CC1-99AB-6A08E960EAB2Q34810763-E9589BAE-E65F-4EAB-8E89-F07236FB571DQ35076238-BE6C26A7-25FD-4235-BEF4-66A1830948EEQ35076255-8F237F9E-0084-4064-947F-8C91DA83B1A1Q35087326-E71232CC-4B44-43FB-AECD-EB7414F5266EQ35144004-60F27673-8273-437C-BA2F-9D7A3D5A7A6AQ35563035-43AB52A3-414E-4292-9C94-E5D61AE91EBFQ35624530-BD6C7ABE-198D-4431-A650-EF78CD5AAA0FQ35779283-9D51C6BA-5846-462C-BEB2-7B79EF12C544Q35837917-57F17410-6E3C-428B-B0AD-D888D5CA9012
P2860
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@ast
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@en
type
label
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@ast
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@en
prefLabel
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@ast
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@en
P2093
P921
P356
P1476
Phase II trial of gemcitabine ...... denocarcinoma of the pancreas.
@en
P2093
B Trochanowski
C D Flombaum
D P Kelsen
E S Casper
P G Tarassoff
R T Heelan
P2888
P356
10.1007/BF00873232
P577
1994-01-01T00:00:00Z
P6179
1041773148